Mobile

Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 with and without RBV in Subjects With Chronic Hepatitis C V...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002927-90

Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 with and without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the efficacy and safety of ABT-493 and ABR-530 (or ABT-493/ABT-530) with or without RBV in subjects with chronic HCV genotype 2, 3, 4, 5 or 6 infection. In Part 4, the primary objectives include to assess the efficacy (SVR12) of treatment with the ABT-493/ABT-530 combination regimen in GT2-infected DAA-naïve subjects without cirrhosis compared to a historical SVR12 rate of treatment with sofosbuvir plus RBV in GT2-infected DAA-naïve subjects without cirrhosis.

Critère d'inclusion

  • Chronic Hepatitis C Virus (HCV) Infection

Liens